

POSTERS

P-1 - Risk of Developing Thyroid Eye Disease in Patients with Thyroid Dysfunction that Received a COVID-19 Vaccination.

Linus Amarikwa, Patcharaporn Chandraparnik, Chrysoula Dosiou, Andrea Lora Kossler

P-2 - Incidence Of Thyroid Eye Disease in Graves' Disease Patients treated with Antithyroid Therapy only, Radioiodine, or Thyroidectomy – A Nationwide Registry-Based Cohort Study.

Lena Boulakh, Jonas L. Isaksen, Steffen Heegaard, Helena Buch Hesgaard, Jorgen Kim Kanters, Birte Nygaard, Henrik Enghousen Poulsen, Peter Bjerre Toft, Andrea L. Kossler, Christina Ellervik

P-3 - Orbital Echographic Assessment of Extraocular Muscle Size Changes Associated with Teprotumumab.

Lindsay Chun, Julia Fleecs, Chau Pham, Erin Shriver

P-4 - Effect of Teprotumumab on Thyroid Stimulating Immunoglobulin.

Lindsay Chun, Julia Fleecs, Chau Pham, Erin Shriver

P-5 - Thyroid Eye Disease Manifesting After Intravitreal Injections.

Kayla Danesh, Jessica R. Chang

P-6 - Teprotumumab (Tepezza)-Related Hyperglycemia is Associated with Baseline Glycemic Status in Thyroid Eye Disease.

Tracy Lang, Aaron Rael, Jessica Chang, Sandy Zhang-Nunes

P-7 -THRIVE and THRIVE-2: Phase 3 Trials of VRDN-001 in Thyroid Eye Disease: Next Generation Insulin-like Growth Factor-1 Receptor Blockade.

Steven Leibowitz, Thomas Ciulla

P-8 - Volumetric and Density Analysis of Compressive Optic Neuropathy in Patients with Thyroid Eye Disease.

Joy Li, Joyce Wen, Kristen Park, Shirley Li

P-9 - A Comparison of Extraocular Muscle Maximum Diameter and Volume in Thyroid Eye Disease.

Nicolas Malkoff, Kayla Danesh, Kristen Park, Chang Jessica

P-10 - A Novel Association Between Human Papillomavirus and Thyroid Eye Disease.

Benjamin Meyer, Ishita Garg, Daniel Pelaez, Sara Wester

P-11 - Pharmacokinetic and Safety Results of VRDN-003, a Full Antagonist Antibody to the IGF-1 Receptor for Thyroid Eye Disease (TED) in Healthy Volunteers: Potential for Subcutaneous Administration.

Raghu Mudumbai, Kelly Foster, Brent Dickinson, Abiola Matthew

P-12 - Thyroid Eye Disease Plus IgG4 Related Disease.

Farzad Pakdel, Niloofar Pirmarzashti, Annousheh Haghighi, Zohre Nozarian

P-13 - Efficacy of Anti-TNF-alpha agents in Active Thyroid Eye Disease.

Farzad Pakdel, Niloofar Pirmarzashti, Annousheh Haghighi, Zohre Nozarian

P-14 - Rates of rehabilitative surgeries in patients with thyroid eye disease treated with intravenous steroids versus teprotumumab.

William Pike, Adeola Ishola, Andrea Kossler, Chrysoula Dosiou

P-15 - Recurrent or Progressive Dysthyroid Optic Neuropathy After Teprotumumab Therapy: A Case Series.

Shreya Shah, Pat Chandraparnik, Chrysoula Dosiou, Andrea Kossler

P-16 - LASN01, a high affinity anti-Interleukin-11 receptor (IL-11R) antibody, potentially provides a novel treatment option for treatment of thyroid eye disease (TED) patients, regardless of prior treatments including Teprotumumab.

James Swaney, Shira Geller, Yasmin Vasquez, Toni Jun

P-17 - Development of novel objective outcomes parameters in thyroid eye disease.

Jimmy Uddin, Mohsan Malik

P-18 - Optimal Surgery Timing for Patients with Thyroid Eye Disease Treated with Teprotumumab: A Collaborative Multicenter Study.

Hannah Walsh, Benjamin Meyer, Kevin Clauss, Sara Wester

P-19 - Blocking IL-6 and hyaluronic acid production in TED adipocytes with a novel TSHR nonpeptide antagonist and K1-70.

Collynn Woeller, Eliza Roztocil, Steven Feldon, Elizabeth Rico-Bautista

P-20 - Role of Wnt signaling in chronic TED.

Albert Wu, Aditi Swarup, Johnathan Chen